nitrates has been researched along with Pulmonary Hypertension in 58 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to evaluate the role of plasma endothelin-1 (ET-1) and nitrate levels in DS children with complete AVSD-associated pulmonary hypertension (PH) and compare this to ND patients." | 7.75 | Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children. ( Karademir, S; Karakurt, C; Ocal, B; Oğuz, D; Senocak, F; Sungur, M, 2009) |
| "These results suggest that pretreatment with atorvastatin attenuates APE-induced pulmonary hypertension and increases 24-hr survival rate by mechanisms that result in attenuated increases in lung activated MMP-9 after APE." | 7.74 | Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. ( Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE, 2007) |
| "To investigate the interaction between nitric (NO) / nitric oxygenase (NOS) and hydrogen sulfide (H(2)S)/ cystathionine-gamma-lyase (CSE) system in the pathogenesis of hypoxic pulmonary hypertension." | 7.72 | [Interaction between endogenous nitric oxide and hydrogen sulfide in pathogenesis of hypoxic pulmonary hypertension]. ( Du, JB; Shi, L; Tang, CS; Yan, H; Zhang, CY; Zhang, QY, 2004) |
| "We determined whether vasodilator doses of inhaled nitric oxide (NO) prevented the progression of pulmonary hypertension (PH) and vascular changes in monocrotaline-induced PH." | 7.69 | Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. ( Kitabatake, M; Maruyama, J; Maruyama, K; Mitani, Y; Miyasaka, K; Yamauchi, T, 1997) |
| "Monocrotaline (MCT)-induced pulmonary hypertension (PH) is associated with impaired endothelium-dependent nitric oxide (NO)-mediated relaxation." | 7.69 | Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. ( Gewitz, MH; Gloster, ES; Mathew, R; Sundararajan, T; Thompson, CI; Zeballos, GA, 1997) |
| "Symptomatic treatment of pulmonary hypertension aims at reducing right ventricular afterload in order to delay the development of ventricular failure." | 6.38 | [Use of nitrates in the symptomatic treatment of pulmonary hypertension]. ( Dubiel, JP, 1989) |
| "Sildenafil attenuates acute pulmonary embolism-induced pulmonary hypertension." | 5.33 | Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. ( Dias-Junior, CA; Evora, PR; Moreno, H; Souza-Silva, AR; Tanus-Santos, JE; Uzuelli, JA, 2005) |
| " We aimed to evaluate the role of plasma endothelin-1 (ET-1) and nitrate levels in DS children with complete AVSD-associated pulmonary hypertension (PH) and compare this to ND patients." | 3.75 | Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children. ( Karademir, S; Karakurt, C; Ocal, B; Oğuz, D; Senocak, F; Sungur, M, 2009) |
| "These results suggest that pretreatment with atorvastatin attenuates APE-induced pulmonary hypertension and increases 24-hr survival rate by mechanisms that result in attenuated increases in lung activated MMP-9 after APE." | 3.74 | Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. ( Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE, 2007) |
| "To investigate the interaction between nitric (NO) / nitric oxygenase (NOS) and hydrogen sulfide (H(2)S)/ cystathionine-gamma-lyase (CSE) system in the pathogenesis of hypoxic pulmonary hypertension." | 3.72 | [Interaction between endogenous nitric oxide and hydrogen sulfide in pathogenesis of hypoxic pulmonary hypertension]. ( Du, JB; Shi, L; Tang, CS; Yan, H; Zhang, CY; Zhang, QY, 2004) |
| " The objective of this study was to test the hypothesis that secondary model aerosols exert acute pulmonary adverse effects in rats, and that rats with pulmonary hypertension (PH), induced by monocrotaline (MCT), are more sensitive to these components than normal healthy animals." | 3.71 | Pulmonary effects of ultrafine and fine ammonium salts aerosols in healthy and monocrotaline-treated rats following short-term exposure. ( Arts, JH; Boere, AJ; Cassee, FR; Dormans, JA; Fokkens, PH; Spoor, SM; van Bree, L, 2002) |
| "The endogenous production of metabolites of the L-arginine-NO pathway has been found to be altered in patients with left-to-right shunt and pulmonary hypertension." | 3.71 | Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt. ( Bettendorf, M; Fiehn, W; Gorenflo, M; Pöge, A; Ulmer, HE; Werle, E; Zheng, C, 2001) |
| "All animals responded to oleic acid injection with rapid development of pulmonary hypertension and deterioration of PaO2 and intrapulmonary shunt fraction." | 3.69 | Efficacy of inhaled nitric oxide in a porcine model of adult respiratory distress syndrome. ( Billiar, TR; Exler, R; Imai, T; Jacob, TD; Motoyama, EK; Nakayama, DK; Nishio, I; Peitzman, AB; Shah, NS; Yousem, SA, 1994) |
| "We determined whether vasodilator doses of inhaled nitric oxide (NO) prevented the progression of pulmonary hypertension (PH) and vascular changes in monocrotaline-induced PH." | 3.69 | Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. ( Kitabatake, M; Maruyama, J; Maruyama, K; Mitani, Y; Miyasaka, K; Yamauchi, T, 1997) |
| "The endothelium-derived vasoconstrictor endothelin-1 (ET-1) may be involved in pulmonary hypertension (PH), but production of the endothelium-derived vasodilator nitric oxide (NO) after cardiopulmonary bypass (CPB) in congenital heart disease is unclear." | 3.69 | Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. ( Chang, D; Hiramatsu, T; Hoshino, S; Imai, Y; Nakazawa, M; Takanashi, Y; Tanaka, SA; Yashima, M, 1997) |
| "Monocrotaline (MCT)-induced pulmonary hypertension (PH) is associated with impaired endothelium-dependent nitric oxide (NO)-mediated relaxation." | 3.69 | Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. ( Gewitz, MH; Gloster, ES; Mathew, R; Sundararajan, T; Thompson, CI; Zeballos, GA, 1997) |
| "BRJ administered for 1 week increases pulmonary NO production and the relative arginine bioavailability in patients with PAH, compared with placebo." | 2.87 | Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study. ( Baron, T; Björkstrand, K; Granstam, SO; Hedeland, M; Hedenström, H; Henrohn, D; Ingimarsdóttir, IJ; Jansson, M; Lundberg, JO; Malinovschi, A; Wernroth, ML; Wikström, G, 2018) |
| " A decrease in the production and bioavailability of NO is a hallmark of many major chronic diseases including hypertension, ischaemia-reperfusion injury, atherosclerosis and diabetes." | 2.53 | Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. ( Lundberg, JO; Omar, SA; Webb, AJ; Weitzberg, E, 2016) |
| "Nitric oxide (NO) is a potent vasodilator in the lung, whose bioavailability and signaling pathway are impaired in PAH." | 2.49 | Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics. ( Bueno, M; Gladwin, MT; Mora, AL; Wang, J, 2013) |
| "Symptomatic treatment of pulmonary hypertension aims at reducing right ventricular afterload in order to delay the development of ventricular failure." | 2.38 | [Use of nitrates in the symptomatic treatment of pulmonary hypertension]. ( Dubiel, JP, 1989) |
| "Sildenafil attenuates acute pulmonary embolism-induced pulmonary hypertension." | 1.33 | Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. ( Dias-Junior, CA; Evora, PR; Moreno, H; Souza-Silva, AR; Tanus-Santos, JE; Uzuelli, JA, 2005) |
| "After 5 weeks, MRI showed right ventricular hypertrophy in MCT(+)/ACEI(-) rats." | 1.31 | Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. ( Billiar, TR; Ho, C; Kanno, S; Lee, PC; Wu, YJ, 2001) |
| " L-Arginine was infused at a dosage of 500 mg/kg body weight into the donor pigs (30 min before liver explantation) and also into the recipients (over a period of 3 hr from the beginning of the reperfusion period)." | 1.30 | Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. ( Benditte, H; Grünberger, T; Längle, F; Mittlböck, M; Mühlbacher, F; Roth, E; Schindl, M; Soliman, T; Steininger, R; Waldmann, E; Windberger, U, 1997) |
| "Pulmonary hypertension is a serious complication after cardiopulmonary bypass (CPB)." | 1.29 | Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. ( Buckberg, GD; Ignarro, LJ; Ihnken, K; Morita, K; Sherman, MP, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (10.34) | 18.7374 |
| 1990's | 12 (20.69) | 18.2507 |
| 2000's | 19 (32.76) | 29.6817 |
| 2010's | 17 (29.31) | 24.3611 |
| 2020's | 4 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Shilin, DS | 1 |
| Shapovalov, KG | 1 |
| Huang, L | 1 |
| Pang, L | 1 |
| Gu, Q | 1 |
| Yang, T | 1 |
| Li, W | 1 |
| Quan, R | 1 |
| Su, W | 1 |
| Wu, W | 1 |
| Tang, F | 1 |
| Zhu, X | 1 |
| Shen, J | 1 |
| Sun, J | 2 |
| Shan, G | 1 |
| Xiong, C | 1 |
| Huang, S | 1 |
| He, J | 1 |
| Liu, Y | 2 |
| Croft, KD | 1 |
| Hodgson, JM | 1 |
| Mori, T | 1 |
| Ward, NC | 1 |
| Tawa, M | 1 |
| Nagata, R | 1 |
| Sumi, Y | 1 |
| Nakagawa, K | 1 |
| Sawano, T | 1 |
| Ohkita, M | 1 |
| Matsumura, Y | 1 |
| Evans, CE | 1 |
| Zhao, YY | 1 |
| Henrohn, D | 2 |
| Björkstrand, K | 1 |
| Lundberg, JO | 3 |
| Granstam, SO | 1 |
| Baron, T | 1 |
| Ingimarsdóttir, IJ | 1 |
| Hedenström, H | 1 |
| Malinovschi, A | 2 |
| Wernroth, ML | 1 |
| Jansson, M | 1 |
| Hedeland, M | 1 |
| Wikström, G | 2 |
| Cortés-Puch, I | 1 |
| Schechter, AN | 1 |
| Solomon, SB | 1 |
| Park, JW | 1 |
| Feng, J | 1 |
| Gilliard, C | 1 |
| Natanson, C | 1 |
| Piknova, B | 1 |
| Omar, SA | 1 |
| Webb, AJ | 1 |
| Weitzberg, E | 1 |
| Klinger, JR | 1 |
| Sungur, M | 1 |
| Ocal, B | 1 |
| Oğuz, D | 1 |
| Karademir, S | 1 |
| Karakurt, C | 1 |
| Senocak, F | 1 |
| Ananthakrishnan, M | 1 |
| Barr, FE | 1 |
| Summar, ML | 1 |
| Smith, HA | 1 |
| Kaplowitz, M | 1 |
| Cunningham, G | 1 |
| Magarik, J | 1 |
| Zhang, Y | 1 |
| Fike, CD | 1 |
| Ingram, TE | 1 |
| Pinder, AG | 1 |
| Bailey, DM | 1 |
| Fraser, AG | 1 |
| James, PE | 1 |
| Jin, Y | 2 |
| Calvert, TJ | 1 |
| Chen, B | 1 |
| Chicoine, LG | 2 |
| Joshi, M | 1 |
| Bauer, JA | 1 |
| Nelin, LD | 2 |
| Cua, CL | 1 |
| Rogers, LK | 1 |
| Augustine, M | 1 |
| Nash, PL | 1 |
| Eriksson, A | 1 |
| Alving, K | 1 |
| Ibrahim, YI | 1 |
| Ninnis, JR | 1 |
| Hopper, AO | 1 |
| Deming, DD | 1 |
| Zhang, AX | 1 |
| Herring, JL | 1 |
| Sowers, LC | 1 |
| McMahon, TJ | 2 |
| Power, GG | 1 |
| Blood, AB | 1 |
| Mounier, R | 1 |
| Amonchot, A | 1 |
| Caillot, N | 1 |
| Gladine, C | 1 |
| Citron, B | 1 |
| Bedu, M | 1 |
| Chirico, E | 1 |
| Coudert, J | 1 |
| Pialoux, V | 1 |
| Sparacino-Watkins, CE | 1 |
| Lai, YC | 1 |
| Gladwin, MT | 2 |
| Baliga, RS | 1 |
| Milsom, AB | 1 |
| Ghosh, SM | 1 |
| Trinder, SL | 1 |
| Macallister, RJ | 1 |
| Ahluwalia, A | 2 |
| Hobbs, AJ | 2 |
| Bueno, M | 1 |
| Wang, J | 1 |
| Mora, AL | 1 |
| Rafikova, O | 1 |
| Rafikov, R | 1 |
| Kumar, S | 1 |
| Sharma, S | 1 |
| Aggarwal, S | 1 |
| Schneider, F | 1 |
| Jonigk, D | 1 |
| Black, SM | 4 |
| Tofovic, SP | 1 |
| Tsikas, D | 1 |
| Cassee, FR | 1 |
| Arts, JH | 1 |
| Fokkens, PH | 1 |
| Spoor, SM | 1 |
| Boere, AJ | 1 |
| van Bree, L | 1 |
| Dormans, JA | 1 |
| Millatt, LJ | 1 |
| Whitley, GS | 1 |
| Li, D | 1 |
| Leiper, JM | 1 |
| Siragy, HM | 1 |
| Carey, RM | 1 |
| Johns, RA | 1 |
| Zhang, QY | 1 |
| Du, JB | 1 |
| Shi, L | 1 |
| Zhang, CY | 1 |
| Yan, H | 1 |
| Tang, CS | 1 |
| Sasaki, S | 1 |
| Asano, M | 1 |
| Ukai, T | 1 |
| Nomura, N | 1 |
| Maruyama, K | 2 |
| Manabe, T | 1 |
| Mishima, A | 1 |
| Fratz, S | 1 |
| Meyrick, B | 1 |
| Ovadia, B | 1 |
| Johengen, MJ | 2 |
| Reinhartz, O | 1 |
| Azakie, A | 1 |
| Ross, G | 1 |
| Fitzgerald, R | 1 |
| Oishi, P | 1 |
| Hess, J | 1 |
| Fineman, JR | 3 |
| Fahim, MR | 1 |
| Halim, SM | 1 |
| Kamel, I | 1 |
| Medvedeva, NA | 1 |
| Bonartsev, AP | 1 |
| Postnikov, AB | 1 |
| Slavutskaia, AV | 1 |
| D'iakonov, KB | 1 |
| Brandler, MD | 1 |
| Powell, SC | 1 |
| Craig, DM | 1 |
| Quick, G | 1 |
| Goldberg, RN | 1 |
| Stamler, JS | 1 |
| Souza-Silva, AR | 1 |
| Dias-Junior, CA | 1 |
| Uzuelli, JA | 1 |
| Moreno, H | 2 |
| Evora, PR | 1 |
| Tanus-Santos, JE | 3 |
| Souza-Costa, DC | 1 |
| Figueiredo-Lopes, L | 1 |
| Alves-Filho, JC | 1 |
| Semprini, MC | 1 |
| Gerlach, RF | 1 |
| Cunha, FQ | 1 |
| Gorenflo, M | 2 |
| Herpel, E | 1 |
| Ullmann, MV | 1 |
| Röhlig, K | 1 |
| Demirakca, S | 1 |
| Klimpel, H | 1 |
| Hagl, S | 1 |
| Gebhard, MM | 1 |
| Schnabel, PA | 1 |
| Shah, NS | 1 |
| Nakayama, DK | 1 |
| Jacob, TD | 1 |
| Nishio, I | 1 |
| Imai, T | 1 |
| Billiar, TR | 2 |
| Exler, R | 1 |
| Yousem, SA | 1 |
| Motoyama, EK | 1 |
| Peitzman, AB | 1 |
| Morita, K | 1 |
| Ihnken, K | 1 |
| Buckberg, GD | 1 |
| Sherman, MP | 1 |
| Ignarro, LJ | 1 |
| Maruyama, J | 1 |
| Mitani, Y | 1 |
| Kitabatake, M | 1 |
| Yamauchi, T | 1 |
| Miyasaka, K | 1 |
| Hiramatsu, T | 1 |
| Imai, Y | 1 |
| Takanashi, Y | 1 |
| Hoshino, S | 1 |
| Yashima, M | 1 |
| Tanaka, SA | 1 |
| Chang, D | 1 |
| Nakazawa, M | 1 |
| Mathew, R | 1 |
| Gloster, ES | 1 |
| Sundararajan, T | 1 |
| Thompson, CI | 1 |
| Zeballos, GA | 1 |
| Gewitz, MH | 1 |
| Längle, F | 1 |
| Steininger, R | 1 |
| Waldmann, E | 1 |
| Grünberger, T | 1 |
| Benditte, H | 1 |
| Mittlböck, M | 1 |
| Soliman, T | 1 |
| Schindl, M | 1 |
| Windberger, U | 1 |
| Mühlbacher, F | 1 |
| Roth, E | 1 |
| Seghaye, MC | 1 |
| Duchateau, J | 1 |
| Bruniaux, J | 1 |
| Demontoux, S | 1 |
| Détruit, H | 1 |
| Bosson, C | 1 |
| Lecronier, G | 1 |
| Mokhfi, E | 1 |
| Serraf, A | 1 |
| Planché, C | 1 |
| Avontuur, JA | 1 |
| Biewenga, M | 1 |
| Buijk, SL | 1 |
| Kanhai, KJ | 1 |
| Bruining, HA | 1 |
| Jacobs, BR | 1 |
| Brilli, RJ | 1 |
| Ballard, ET | 1 |
| Passerini, DJ | 1 |
| Smith, DJ | 1 |
| Moreno, RA | 1 |
| Martins, ML | 1 |
| Pereira, R | 1 |
| de Nucci, G | 1 |
| McMullan, DM | 2 |
| Bekker, JM | 2 |
| Parry, AJ | 1 |
| Kon, A | 1 |
| Heidersbach, RS | 1 |
| Mizutani, T | 1 |
| Takahashi, S | 1 |
| Kihara, S | 1 |
| Toyooka, H | 1 |
| Beckman, JS | 1 |
| Wedgwood, S | 1 |
| Kanno, S | 1 |
| Wu, YJ | 1 |
| Lee, PC | 1 |
| Ho, C | 1 |
| Zheng, C | 1 |
| Pöge, A | 1 |
| Bettendorf, M | 1 |
| Werle, E | 1 |
| Fiehn, W | 1 |
| Ulmer, HE | 1 |
| Biddle, TL | 1 |
| Zeh, E | 1 |
| Vorob'ev, LP | 1 |
| Maev, IV | 1 |
| Paleev, NR | 1 |
| Tsar'kova, LN | 1 |
| Chereĭskaia, NK | 1 |
| Baklykova, SN | 1 |
| Dubiel, JP | 1 |
| Hughes, JD | 1 |
| Rubin, LJ | 1 |
| Sil'vestrov, VP | 1 |
| Surovov, IuA | 1 |
| Semin, SN | 1 |
| Pakulin, IA | 1 |
| Larin, NV | 1 |
| Baruzzi, AC | 1 |
| Knobel, E | 1 |
| Fernandes Júnior, CJ | 1 |
| Andrei, AM | 1 |
| Akamine, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China[NCT02164526] | 520 participants (Anticipated) | Observational [Patient Registry] | 2013-01-31 | Recruiting | |||
| Dietary Nitrates for Heart Failure[NCT01682356] | Phase 1/Phase 2 | 126 participants (Anticipated) | Interventional | 2012-01-31 | Active, not recruiting | ||
| Improving Prematurity-Related Respiratory Outcomes at Vanderbilt: The Prematurity and Respiratory Outcomes Program (PROP)[NCT01460576] | 253 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial[NCT05450328] | Phase 2 | 141 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose
| Intervention | picomoles O2/min (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -17.58 |
| WHO Group II Pulmonary Hypertension (PH) | 8.62 |
| WHO Group III Pulmonary Hypertension (PH) | -11.64 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.9 |
| WHO Group II Pulmonary Hypertension (PH) | 7.0 |
| WHO Group III Pulmonary Hypertension (PH) | 7.4 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.2 |
| WHO Group III Pulmonary Hypertension (PH) | 2.4 |
Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled
| Intervention | dyne*sec/cm5 (Median) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.004 |
| WHO Group II Pulmonary Hypertension (PH) | -0.34 |
| WHO Group III Pulmonary Hypertension (PH) | -0.20 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | Woods units (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 0.77 |
| WHO Group II Pulmonary Hypertension (PH) | 0.40 |
| WHO Group III Pulmonary Hypertension (PH) | -0.39 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -5.1 |
| WHO Group II Pulmonary Hypertension (PH) | -3.4 |
| WHO Group III Pulmonary Hypertension (PH) | -9.5 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg⋅min/L (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.43 |
| WHO Group II Pulmonary Hypertension (PH) | 1.19 |
| WHO Group III Pulmonary Hypertension (PH) | -2.04 |
Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose
| Intervention | minutes (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 42.0 |
| WHO Group II Pulmonary Hypertension (PH) | 33.0 |
| WHO Group III Pulmonary Hypertension (PH) | 42.5 |
8 reviews available for nitrates and Pulmonary Hypertension
| Article | Year |
|---|---|
Mechanisms of the protective effects of nitrate and nitrite in cardiovascular and metabolic diseases.
Topics: Animals; Blood Pressure; Diabetes Mellitus; Endothelium, Vascular; Humans; Hypertension, Pulmonary; | 2020 |
Molecular Basis of Nitrative Stress in the Pathogenesis of Pulmonary Hypertension.
Topics: Animals; Humans; Hypertension, Pulmonary; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Oxidative S | 2017 |
Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases.
Topics: Animals; Biological Availability; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Di | 2016 |
Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics.
Topics: Animals; Humans; Hypertension, Pulmonary; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Vas | 2013 |
[New trends in the treatment of hemodynamic disorders in liver cirrhosis].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Drug Evaluation; Hem | 1991 |
[Use of nitrates in the symptomatic treatment of pulmonary hypertension].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Nitrates; Pulmonary Artery; Pulmonary Circulation | 1989 |
Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aminorex; Anticoagulants; Autoimmune Diseases; Calc | 1986 |
[Right ventricle function].
Topics: Coronary Disease; Heart Ventricles; Humans; Hypertension, Pulmonary; Myocardial Contraction; Nitrate | 1986 |
3 trials available for nitrates and Pulmonary Hypertension
| Article | Year |
|---|---|
Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Topics: Adult; Aged; Aged, 80 and over; Beta vulgaris; Cross-Over Studies; Dietary Supplements; Double-Blind | 2018 |
Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite.
Topics: Adult; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Echocardiography; Humans; H | 2010 |
Inhaled nitric oxide therapy increases blood nitrite, nitrate, and s-nitrosohemoglobin concentrations in infants with pulmonary hypertension.
Topics: Administration, Inhalation; Adult; Female; Hemoglobins; Humans; Hypertension, Pulmonary; Infant; Inf | 2012 |
47 other studies available for nitrates and Pulmonary Hypertension
| Article | Year |
|---|---|
Changes in Some Vascular Biomarkers in Patients with Severe COVID-19 with Various Degrees of Pulmonary Hypertension.
Topics: Biomarkers; COVID-19; Endothelin-1; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Nit | 2022 |
Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China.
Topics: Coronary Artery Disease; Creatinine; Heart Failure; Humans; Hypertension, Pulmonary; Nitrates; Preva | 2022 |
Preventive effects of nitrate-rich beetroot juice supplementation on monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Beta vulgaris; Blood Pressure; Dietary Supplements; Fruit and Vegetable Juices; Hypertensio | 2021 |
Inhaled nebulized nitrite and nitrate therapy in a canine model of hypoxia-induced pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Dogs; Hypertension, Pulmonary; Hypoxia; Nitrates; Nitric Oxide; | 2019 |
Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?
Topics: Biomarkers; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Nitrates; Nitr | 2016 |
Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children.
Topics: Child; Child, Preschool; Down Syndrome; Endothelin-1; Female; Heart Septal Defects, Atrial; Heart Se | 2009 |
L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Topics: Amino Acids; Animals; Animals, Newborn; Blotting, Western; Chronic Disease; Citrulline; Exhalation; | 2009 |
Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.
Topics: Animals; Arginase; Blotting, Western; Body Weight; Chronic Disease; Dual Specificity Phosphatase 1; | 2010 |
Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.
Topics: Arginine; Biomarkers; Down Syndrome; Female; Humans; Hypertension, Pulmonary; Infant; Male; Nitrates | 2011 |
Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension.
Topics: Adult; Aged; Breath Tests; Bronchi; Case-Control Studies; Exhalation; Familial Primary Pulmonary Hyp | 2011 |
Pulmonary arterial systolic pressure and susceptibility to high altitude pulmonary edema.
Topics: Adult; Altitude Sickness; Blood Pressure; Disease Susceptibility; Echocardiography, Doppler; Enzyme- | 2011 |
Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics.
Topics: Animals; Hypertension, Pulmonary; Male; Nitrates; Nitric Oxide Synthase Type III; Xanthine Dehydroge | 2012 |
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase.
Topics: Allopurinol; Animal Feed; Animals; Antibiotics, Antineoplastic; Bleomycin; Cyclic GMP; Disease Model | 2012 |
Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Female; Hypertension, Pulmonary; Nitrates; Nitrosation; O | 2013 |
Letter by Tsikas regarding article, "dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase".
Topics: Animals; Hypertension, Pulmonary; Male; Nitrates; Nitric Oxide Synthase Type III; Xanthine Dehydroge | 2012 |
Letter by Ahluwalia and Hobbs regarding article, "Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics".
Topics: Animals; Hypertension, Pulmonary; Male; Nitrates; Nitric Oxide Synthase Type III; Xanthine Dehydroge | 2013 |
Pulmonary effects of ultrafine and fine ammonium salts aerosols in healthy and monocrotaline-treated rats following short-term exposure.
Topics: Administration, Inhalation; Aerosols; Air Pollutants; Ammonium Sulfate; Animals; Bronchoalveolar Lav | 2002 |
Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.
Topics: Amidohydrolases; Animals; Arginine; Blotting, Western; Chronic Disease; Disease Models, Animal; Enzy | 2003 |
[Interaction between endogenous nitric oxide and hydrogen sulfide in pathogenesis of hypoxic pulmonary hypertension].
Topics: Animals; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Male; NG-Nitroarginine Methyl Ester; Ni | 2004 |
Nitric oxide formation and plasma L-arginine levels in pulmonary hypertensive rats.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Endothelin-1; Endothelium, Vascular; Hypertension, P | 2004 |
Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure.
Topics: Animals; Aspartic Acid Endopeptidases; Cyclic GMP; Endothelin A Receptor Antagonists; Endothelin-1; | 2004 |
The role of oxidative products of nitrous oxide and the tumor necrosis factor alpha in dilated cardiomyopathy.
Topics: Analysis of Variance; Blood Pressure; Cardiomyopathy, Dilated; Diastole; Echocardiography; Female; H | 2004 |
[Decrease of nitric oxide (NO)-cGMP-dependent vasodilatation in the vessels of lesser circulation in endothelial dysfunction].
Topics: Animals; Cyclic GMP; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Guanidines; H | 2005 |
A novel inhaled organic nitrate that affects pulmonary vascular tone in a piglet model of hypoxia-induced pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Hypo | 2005 |
Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension.
Topics: Acute Disease; Analysis of Variance; Animals; Arginine; Blood Pressure; Cyclic GMP; Dogs; Female; He | 2005 |
Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9.
Topics: Acute Disease; Analysis of Variance; Animals; Atorvastatin; Disease Models, Animal; Drug Evaluation, | 2007 |
Pulmonary vascular changes in piglets with increased pulmonary blood flow and pressure.
Topics: Animals; Animals, Newborn; Aspartic Acid Endopeptidases; Blood Pressure; Cyclic GMP; Endothelin-1; E | 2007 |
Efficacy of inhaled nitric oxide in a porcine model of adult respiratory distress syndrome.
Topics: Administration, Inhalation; Animals; Blood Pressure; Dose-Response Relationship, Drug; Extravascular | 1994 |
Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass.
Topics: Animals; Antioxidants; Cardiopulmonary Bypass; Catalase; Endothelium, Vascular; Hypertension, Pulmon | 1996 |
Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats.
Topics: Administration, Inhalation; Animals; Blood Pressure; Body Water; Dose-Response Relationship, Drug; G | 1997 |
Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects.
Topics: Cardiopulmonary Bypass; Case-Control Studies; Child; Child, Preschool; Endothelin-1; Female; Heart D | 1997 |
Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Arterioles; Blood Pressure; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inject | 1997 |
Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation.
Topics: Animals; Arginine; Blood Urea Nitrogen; Cardiac Output; Female; Hemodynamics; Humans; Hypertension, | 1997 |
Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations.
Topics: Atrial Natriuretic Factor; Blood Pressure; Cardiopulmonary Bypass; Cyclic GMP; Heart Failure; Heart | 1997 |
Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock.
Topics: Aged; Cardiac Output; Enzyme Inhibitors; Hemodynamics; Humans; Hypertension, Pulmonary; Male; NG-Nit | 1998 |
Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury.
Topics: Administration, Inhalation; Aerosols; Amino Acids, Diamino; Animals; Cardiac Catheterization; Cardia | 1998 |
Inhaled nitric oxide improves hemodynamics during a venous air infusion (VAI) in dogs.
Topics: Administration, Inhalation; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Emb | 1999 |
Alterations in endogenous nitric oxide production after cardiopulmonary bypass in lambs with normal and increased pulmonary blood flow.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Blotting, Western; Cardiopulmonary Bypass; Cyclic GMP; | 2000 |
Repeated administration of protamine does not attenuate circulatory changes caused by protamine reversal of heparin in dogs.
Topics: Animals; Anticoagulants; Dogs; Hemodynamics; Heparin; Heparin Antagonists; Hypertension, Pulmonary; | 2001 |
-OONO: rebounding from nitric oxide.
Topics: Administration, Inhalation; Animals; Endothelium, Vascular; Epoprostenol; Hemoglobins; Humans; Hydro | 2001 |
Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy.
Topics: Administration, Inhalation; Animals; Blotting, Western; Cells, Cultured; Dioxoles; Disease Models, A | 2001 |
Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cells, Cultured; Cyclin-Dependent | 2001 |
Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt.
Topics: Adolescent; Adult; Age Factors; Arginine; Arteriovenous Shunt, Surgical; Cardiac Catheterization; Ca | 2001 |
Hemodynamic concepts in treating acute pulmonary edema.
Topics: Aminophylline; Blood Gas Analysis; Cardiac Output; Digitalis Glycosides; Furosemide; Hemodynamics; H | 1977 |
[Letter: Therapy of severe pulmonary hypertension].
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nitrates; Secologanin Tryptamine Alkaloids | 1975 |
[Treatment of patients with chronic obstructive bronchitis and pulmonary hypertension during ambulatory care].
Topics: Adrenergic beta-Agonists; Bronchitis; Chronic Disease; Climate; Delayed-Action Preparations; Dipyrid | 1990 |
[Corrective effect of nitrates and calcium antagonists on hemodynamics and ventilation in chronic bronchitis patients with a syndrome of pulmonary hypertension].
Topics: Bronchitis; Calcium Channel Blockers; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, | 1987 |